Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Goldschmidt

Showing results (361-370 of 539) with videos related to

Pageof 54
Sort By:
Leukemia|May 19, 2021
JunB is a key regulator of multiple myeloma bone marrow angiogenesisFengjuan Fan, Stefano Malvestiti, Sonia Vallet, et al.
Leukemia|June 9, 2018
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)Alessandra Larocca, Sandra Maria Dold, Sonja Zweegman, et al.
Blood Advances|January 19, 2018
Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myelomaMaximilian Merz, Anna Jauch, Thomas Hielscher, et al.
Blood|June 25, 2010
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patientsAnnemiek Broyl, Dirk Hose, Henk Lokhorst, et al.
Blood|April 7, 2006
Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myelomaNiels W C J van de Donk, Nicolaus Kröger, Ute Hegenbart, et al.
Blood Advances|July 6, 2021
Search for AL amyloidosis risk factors using Mendelian randomizationCharlie N Saunders, Subhayan Chattopadhyay, Stefanie Huhn, et al.
Nature Communications|November 30, 2021
Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomicsStephan M Tirier, Jan-Philipp Mallm, Simon Steiger, et al.
Journal for Immunotherapy of Cancer|October 17, 2022
IgE type multiple myeloma exhibits hypermutated phenotype and tumor reactive T cellsNiklas Kehl, Michael Kilian, Julius Michel, et al.
European Journal of Haematology|November 11, 2025
Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG-MM5 TrialTim Richardson, Elias Mai, Ekaterina Menis, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 1, 2025
Validation of novel low-dose CT methods for quantifying bone marrow in the appendicular skeleton of patients with multiple myeloma: initial results from the [<sup>18</sup>F]FDG PET/CT sub-study of the Phase 3 GMMG-HD7 TrialChristos Sachpekidis, Marina Hajiyianni, Martin Grözinger, et al.
Pageof 54

Showing results (361-370 of 539) with videos related to

Sort By:
Pageof 54
Leukemia|May 19, 2021
JunB is a key regulator of multiple myeloma bone marrow angiogenesisFengjuan Fan, Stefano Malvestiti, Sonia Vallet, et al.
Leukemia|June 9, 2018
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)Alessandra Larocca, Sandra Maria Dold, Sonja Zweegman, et al.
Blood Advances|January 19, 2018
Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myelomaMaximilian Merz, Anna Jauch, Thomas Hielscher, et al.
Blood|June 25, 2010
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patientsAnnemiek Broyl, Dirk Hose, Henk Lokhorst, et al.
Blood|April 7, 2006
Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myelomaNiels W C J van de Donk, Nicolaus Kröger, Ute Hegenbart, et al.
Blood Advances|July 6, 2021
Search for AL amyloidosis risk factors using Mendelian randomizationCharlie N Saunders, Subhayan Chattopadhyay, Stefanie Huhn, et al.
Nature Communications|November 30, 2021
Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomicsStephan M Tirier, Jan-Philipp Mallm, Simon Steiger, et al.
Journal for Immunotherapy of Cancer|October 17, 2022
IgE type multiple myeloma exhibits hypermutated phenotype and tumor reactive T cellsNiklas Kehl, Michael Kilian, Julius Michel, et al.
European Journal of Haematology|November 11, 2025
Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG-MM5 TrialTim Richardson, Elias Mai, Ekaterina Menis, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 1, 2025
Validation of novel low-dose CT methods for quantifying bone marrow in the appendicular skeleton of patients with multiple myeloma: initial results from the [<sup>18</sup>F]FDG PET/CT sub-study of the Phase 3 GMMG-HD7 TrialChristos Sachpekidis, Marina Hajiyianni, Martin Grözinger, et al.
Pageof 54